

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

POSITIVE PROFIT ALERT

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 Laws of Hong Kong).

The Company wishes to inform the shareholders (the “**Shareholders**”) and the potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (IFRS)) for the six months ended June 30, 2025, it is expected that the revenue of the Company for the six months ended June 30, 2025 will increase approximately 16%; the gross profit margin will expand approximately 3.6% year-on-year; the profit of the Company and the profit attributable to equity shareholders of the Company for the six months ended June 30, 2025 will increase approximately 54% and approximately 56%, respectively; and after adjusting for share-based compensation expenses, foreign exchange gain & loss, and gain & loss from equity investments, the non-IFRS adjusted net profit of the Company will increase approximately 11%, compared with those for the corresponding period of last year. Such increase was primarily attributable to, among other factors:

- (i) the successful execution of the Group’s “Follow and Win the Molecule” strategies, coupled with its leading technology platforms, best-in-industry timeline and excellent execution track record, contributing to the revenue growth of the Group;
- (ii) enlarged spectrum of services offered to the biologics industry by the Group, including discovery services, pre-IND development services, clinical and commercial manufacturing services, from fast growing technology platforms such as ADC (Antibody-drug Conjugate) and Bispecific Antibodies;

- (iii) growth of research services revenue generated from the Group's various cutting-edge technologies;
- (iv) the utilization of existing and newly expanded capacities, including ramp-up of the Group's manufacturing facility in Europe;
- (v) the cost savings and efficiency improvements achieved through the Group's WuXi Biologics Business System (WBS) and digitalization initiatives; and
- (vi) investment gains from the Company's investment and incubating portfolio.

The Company is still in the process of finalizing the interim results of the Group for the six months ended June 30, 2025. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2025, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit committee of the board of directors of the Company. Shareholders and potential investors of the Company should refer to the interim results announcement of the Group for the six months ended June 30, 2025, which is expected to be published on August 19, 2025.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, July 24, 2025

*As at the date of this announcement, the board of directors ("**Directors**") of the Company comprises Dr. Zhisheng Chen and Dr. Sherry Xuejun Gu as executive Directors; Dr. Ge Li, Mr. Yanling Cao and Ms. Jingwen Miao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.*

** For identification purpose only*